Anna Vilgelm

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients. Read More

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. Read More

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients. Read More

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances. Read More